Clinical analysis of 155 young female patients with breast cancer
10.3760/cma.j.issn.1006-9801.2011.02.005
- VernacularTitle:青年女性乳腺癌155例临床分析
- Author:
Bing SUN
;
Xiangying MENG
;
Shikai WU
;
Tao WANG
;
Shaohua ZHANG
;
Min ZENG
;
Zefei JIANG
;
Santai SONG
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Lymphatic metastasis;
Prognosis
- From:
Cancer Research and Clinic
2011;23(2):88-90,96
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinic characteristics, lifetime and prognostic factors of young female breast cancer patients. MethodsClinical data of 155 patients under 35 years of age with breast cancer were retrospectively reviewed and followed up.ResultsThe positive rate of hormone receptors was 61.6 % (77/125) in all cases who had been detected receptor status. The median survival time in hormone receptors positive and negative group were 119.0 and 51.3 months (P＜0.01), and 5-year survival rates were 68 % and 33 %, respectively. For patients who had been treated with adjuvant tamoxifen (47.1%), the median survival time was 182 months which longer than without tamoxifen (P ＜0.05). The median disease-free survival time and median survival time were 24 and 91 months in all cases. The overall 3-, 5- and 10-year survival rates were 79 %, 60 % and 51%, respectively. Multifactor analysis with the COX model indicated that tumor size, axillary metastatic status, tamoxifen treatment and overexpression of Her-2 were independent prognostic factors. While clinic stage and hormone receptors status might be referenced prognostic factors. ConclusionYoung women breast cancer patient may have good prognosis if multimodality treatment is conducted. Tumor size, axillary metastatic status, adjuvant endocrine therapy and overexpression of Her-2 are independent prognostic factors.
